Navigating AI in Healthcare: Expert Insights and FDA Draft Guidance
Guillaume Gigon
Vice-President, Technology and AI
Navigating AI risks in healthcare just got easier with the FDA’s new draft guidance and explanations from Guillaume Gigon, Innovaderm’s VP of Technology and AI.
You can even comment on the FDA draft document by April 7.
Inderoâs Early Phase 1 model enables sponsors to initiate topical studies that detect early pharmacodynamic signals much sooner than traditional phase 1, using microdosing and transcriptomic analysis. This approach reduces preclinical requirements, shortens study duration from 8â12 weeks to â€3 days, and lowers costs, helping teams make informed go/no-go decisions faster.